Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Stemline Therapeutic (STML)

Stemline Therapeutic (STML)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 396,483
  • Shares Outstanding, K 43,956
  • Annual Sales, $ 500 K
  • Annual Income, $ -85,020 K
  • 60-Month Beta 1.41
  • Price/Sales 794.72
  • Price/Cash Flow N/A
  • Price/Book 3.92

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.40
  • Number of Estimates 6
  • High Estimate -0.31
  • Low Estimate -0.53
  • Prior Year -0.73
  • Growth Rate Est. (year over year) +45.21%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.45 +6.86%
on 10/10/19
11.81 -23.57%
on 09/19/19
-2.53 (-21.89%)
since 09/18/19
3-Month
8.45 +6.86%
on 10/10/19
18.22 -50.44%
on 08/08/19
-4.79 (-34.66%)
since 07/18/19
52-Week
7.82 +15.47%
on 12/21/18
18.22 -50.44%
on 08/08/19
-6.45 (-41.67%)
since 10/18/18

Most Recent Stories

More News
33.6% Return Seen to Date on SmarTrend Stemline Therape Call (STML)

SmarTrend identified a Downtrend for Stemline Therape (NASDAQ:STML) on August 22nd, 2019 at $13.21. In approximately 2 months, Stemline Therape has returned 33.59% as of today's recent price of $8.77....

STML : 9.03 (+0.11%)
Stemline Therapeutics Announces ELZONRIS(R) Clinical Data Selected for Oral Presentation at the 81st Annual Meeting of the Japanese Society of Hematology

Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that ELZONRIS (tagraxofusp)...

STML : 9.03 (+0.11%)
Stemline Therape Has Returned 29.3% Since SmarTrend Recommendation (STML)

SmarTrend identified a Downtrend for Stemline Therape (NASDAQ:STML) on August 22nd, 2019 at $13.21. In approximately 2 months, Stemline Therape has returned 29.34% as of today's recent price of $9.33....

STML : 9.03 (+0.11%)
Stemline Therapeutics Recaps Felezonexor (SL-801) Clinical Data Presentation From ESMO 2019 Congress

Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, presented updated clinical data...

STML : 9.03 (+0.11%)
Stemline Therapeutics Announces Felezonexor (SL-801) Clinical Data to be Featured at Upcoming ESMO 2019 Congress

Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that clinical data...

STML : 9.03 (+0.11%)
Stemline Therapeutics to Present at the 2019 Cantor Global Healthcare Conference

Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that Ivan Bergstein,...

STML : 9.03 (+0.11%)
17.4% Return Seen to Date on SmarTrend Stemline Therape Call (STML)

SmarTrend identified a Downtrend for Stemline Therape (NASDAQ:STML) on August 22nd, 2019 at $13.21. In approximately 1 month, Stemline Therape has returned 17.38% as of today's recent price of $10.91....

STML : 9.03 (+0.11%)
Stemline Therape is Among the Companies in the Biotechnology Industry with the Best Relative Performance (STML , ADMS , MRTX, CHRS , RTRX )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

ADMS : 3.98 (-0.50%)
STML : 9.03 (+0.11%)
MRTX : 76.37 (-12.29%)
Stemline Therapeutics to Present at the Ladenburg Thalmann 2019 Healthcare Conference

Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced that Ivan Bergstein,...

STML : 9.03 (+0.11%)
Downtrend Call Working As Stemline Therape Stock Falls 16.7% (STML)

SmarTrend identified a Downtrend for Stemline Therape (NASDAQ:STML) on August 22nd, 2019 at $13.21. In approximately 4 weeks, Stemline Therape has returned 16.70% as of today's recent price of $11.00....

STML : 9.03 (+0.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong.

See More Share

Trade STML with:

Business Summary

Stemline Therapeutics, Inc. is a biopharmaceutical company developing oncology therapeutics that target cancer stem cells and tumor bulk. The company is developing SL-401, a biologic-drug conjugate, for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine, for pediatric...

See More

Key Turning Points

2nd Resistance Point 9.44
1st Resistance Point 9.23
Last Price 9.03
1st Support Level 8.86
2nd Support Level 8.69

See More

52-Week High 18.22
Fibonacci 61.8% 14.25
Fibonacci 50% 13.02
Fibonacci 38.2% 11.79
Last Price 9.03
52-Week Low 7.82

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar